Jeff Sharman, MD, explores how targeted therapies have transformed CLL treatment and what emerging approaches could shape the future of care.
|Videos|March 18, 2014
The Management of CLL in Elderly Patients
Author(s)Alessandra Ferrajoli, MD
Alessandra Ferrajoli, MD, associate professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the management of chronic lymphocytic leukemia (CLL) in elderly patients.
Advertisement
Alessandra Ferrajoli, MD, associate professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the management of chronic lymphocytic leukemia (CLL) in elderly patients.
Clinical Pearls:
- Clinical trials that have shown that the management of elderly patients with CLL needs to be different from the fit and young population
- Although there is no standard of care for elderly patients with CLL, physicians are starting to move away from chemoimmunotherapy and moving towards monoclonal antibody-based treatment
- In addition to considering the fitness and type of disease of elderly patients, physicians must consider transportation difficulties, limited financial budgets and ease of treatment
Advertisement
Related to this article
New analysis tracks life-years gained from blood cancer therapies, revealing breakthrough inflection points, stubborn AML gaps, and inequities in access.
CELESTIMO trial shows mosunetuzumab plus lenalidomide boosts PFS in relapsed follicular lymphoma, supporting earlier-line outpatient, chemo-free care.
Benjamin Herzberg, MD, discusses KRAS-mutant non–small cell lung cancer, upfront biomarker testing, and the emerging RAS inhibitor toolkit on Targeted Talks.
Broad oncology bundles falter; experts push smaller surgery/radiation episodes, better navigation, and AI analytics to improve value-based care.
In an interview, Peter Voorhees, MD, discusses his presentation of the CERVINO trial data from the International Myeloma Society meeting.
For Prostate Cancer Awareness Month, Herbert Lepor, MD, discusses the leading concerns in managing early prostate cancer and tailoring strategies to the patient based on their risk and goals.
During a roundtable event, Amit R. Mehta, MD, and participants discussed treatment selection for a patient with immune thrombocytopenia at risk of thrombotic events.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Anito-Cel Delivers Durable Responses With Low Neurotoxicity in RRMM
2
Risk, Histology, and Metastatic Site Guide First-Line RCC Treatment Choices
3
FDA Application Withdrawn for I-DXd in Small Cell Lung Cancer
4
Frontline CAR T and Bispecific Antibodies Are the Next Frontier in Myeloma
5